Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01872260
Title Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

progesterone-receptor positive breast cancer

estrogen-receptor positive breast cancer

Therapies

Alpelisib + Letrozole

Alpelisib + Letrozole + Ribociclib

Letrozole + Ribociclib

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.